Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 22:2018:3201203.
doi: 10.1155/2018/3201203. eCollection 2018.

A Clinical Study of Toxication Caused by Carbamazepine Abuse in Adolescents

Affiliations

A Clinical Study of Toxication Caused by Carbamazepine Abuse in Adolescents

Wei Xu et al. Biomed Res Int. .

Abstract

Carbamazepine is known to produce the side effect of euphoria. As such, it lends itself to being a drug of abuse, particularly in the adolescent population. This retrospective study evaluated carbamazepine abuse, treatment course, and associated morbidity in Chinese adolescents. The median dose of carbamazepine resulting in overdose was 2,000 mg (800-5,000). Patients were largely from urban-rural fringe areas (76.47%, 52.94%) with school performance within the last 1/3 range and (52.94%) unsupervised by parents. 35.29% experienced an obvious sense of euphoria. All patients had nervous system symptoms, 6 (35.29%) cases developed coma (GCS < 8), and 5 (29.41%) cases experienced convulsion. Four cases were treated with hemodialysis. The incidence rate in young patients with repeat carbamazepine use and without the supervision of parents was higher than that in first-time users (5/7 versus 4/10), but the difference was not significant. The toxic dose of repeat users was 3428 ± 1035 mg, significantly higher than that of 1470 ± 646 mg in first-time users (P = 0.001). Carbamazepine can produce a sense of euphoria, which is more likely to lead to its abuse and overdose in adolescents. To prevent carbamazepine abuse and overdose will be critical in educating at-risk adolescents and preventing associated morbidities in the future.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Alrashood S. T. Carbamazepine. Profiles of Drug Substances, Excipients and Related Methodology. 2016;41:133–321. doi: 10.1016/bs.podrm.2015.11.001. - DOI - PubMed
    1. Ceron-Litvoc D., Soares B. G., Geddes J., Litvoc J., de Lima M. S. Comparison of carbamazepine and lithium in treatment of bipolar disorder: A systematic review of randomized controlled trials. Journal of Psychopharmacology. 2009;24(1):19–28. doi: 10.1002/hup.990. - DOI - PubMed
    1. Hosseini S. H., Ahmadi A. Abuse potential of carbamazepine for euphorigenic effects. Drug Research. 2015;65(4):223–224. doi: 10.1055/s-0034-1370942. - DOI - PubMed
    1. Sullivan G., Davis S. Is carbamazepine a potential drug of abuse? Journal of Psychopharmacology. 1997;11(1):93–94. doi: 10.1177/026988119701100119. - DOI - PubMed
    1. Degenhardt L., Stockings E., Patton G., Hall W. D., Lynskey M. The increasing global health priority of substance use in young people. The Lancet Psychiatry. 2016;3(3):251–264. doi: 10.1016/S2215-0366(15)00508-8. - DOI - PubMed